Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry

References

• Borowitz M, Chan JKC, Downing JR, et al. B lymphoblastic leukemia/lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, et al. editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2017. p. 200–209.
   Google Scholar
• Smith EC, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96(8):2691–2696.
   PubMed Web of Science ®Google Scholar
• Paietta E. Assessing minimal residual disease (MRD) in leukemia: a changing definition and concept? Bone Marrow Transplant. 2002;29(6):459–465.
   PubMed Web of Science ®Google Scholar
• Borowitz MJ, Pullen DJ, Shuster JJ, et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children’s Oncology Group study . Leukemia. 2003;17(8):1566–1572.
   PubMed Web of Science ®Google Scholar
• Cazzaniga G, Valsecchi MG, Gaipa G, et al. Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia. Br J Haematol. 2011;155(1):45–52.
   PubMed Web of Science ®Google Scholar
• Karawajew L, Dworzak M, Ratei R, et al. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia. Haematologica. 2015;100(7):935–944.
   PubMed Web of Science ®Google Scholar
• Tembhare PR, Ghogale S, Ghatwai N, et al. Evaluation of new markers for minimal residual disease monitoring in B-Cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD assay. Cytometry. 2018;94(1):100–111.
   PubMedGoogle Scholar
• Griesinger F, Piro-Noack M, Kaib N, et al. Leukaemia associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome. Br J Haematol. 1999;105(1):241–255.
   PubMed Web of Science ®Google Scholar
• Dworzak MN, Gaipa G, Ratei R, et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: multicentric assessment is feasible. Cytometry B Clin Cytom. 2008;74(6):331–340.
   PubMedGoogle Scholar
• Bommannan BKK, Arumugam JR, Sundersingh S, et al. CD19 negative and dim precursor B-lineage acute lymphoblastic leukemias: real-world challenges in a targeted-immunotherapy era. Leuk Lymphoma. 2019;60(13):3154–3160.
   PubMed Web of Science ®Google Scholar
• Tembhare P, Badrinath Y, Ghogale S, et al. A novel and easy FxCycle™ violet based flow cytometric method for simultaneous assessment of DNA ploidy and six-color immunophenotyping. Cytometry A. 2016;89(3):281–291.
   PubMedGoogle Scholar
• Van Lochem EG, van der Velden VH, Wind HK, et al. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry B Clin Cytom. 2004;60(1):1–13.
   PubMedGoogle Scholar
• Wood BL. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom. 2016;90(1):47–53.
   PubMed Web of Science ®Google Scholar
• Shaver AC, Greig BW, Mosse CA, et al. B-ALL minimal residual disease flow cytometry: an application of a novel method for optimization of a single-tube model. Am J Clin Pathol. 2015;143(5):716–724.
   PubMed Web of Science ®Google Scholar
• Tembhare PR, Subramanian PG, Ghogale S, et al. A high-sensitivity 10-color flow cytometric minimal residual disease assay in b-lymphoblastic leukemia/lymphoma can easily achieve the sensitivity of 2-in-106 and is superior to standard minimal residual disease assay: a study of 622 patients. Cytometry. 2020;98(1):57–11.
   PubMedGoogle Scholar
• Gaipa G, Basso G, Aliprandi S, et al. Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells. Cytometry B Clin Cytom. 2008;74(3):150–155.
   PubMedGoogle Scholar
• Dworzak MN, Gaipa G, Schumich A, et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group . Cytometry B Clin Cytom. 2010;78(3):147–153.
   PubMedGoogle Scholar
• Sędek L, Theunissen P, Costa ES, et al. Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia. J Immunol Methods. 2019;475:112429.
   PubMed Web of Science ®Google Scholar
• Veltroni M, De Zen L, Sanzari MC, et al. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia. Haematologica. 2003;88(11):1245–1252.
   PubMed Web of Science ®Google Scholar
• Gaipa G, Basso G, Maglia O, et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia. 2005;19(1):49–56.
   PubMed Web of Science ®Google Scholar
• Dworzak MN, Schumich A, Printz D, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood. 2008;112(10):3982–3988.
   PubMed Web of Science ®Google Scholar